What You Should Know: - COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company. - GTC has a very innovative approach to genetic testing, providing molecular information which is critical to determining accurate diagnoses and determining the most appropriate treatment. GTC's tissue and liquid-biopsy testing leverages DNA and RNA sequencing, which is very rare in the
Read More
COTA
HLTH22 Day 1 News Summary: Google, Maven, Highmark, LG, Others
Venture Capital, Private Equity Funding Maven Clinic Secures $90M to Advance End-to-End Family Care Platform Maven Clinic, the largest virtual clinic in women’s and family health raises $90 million Series E funding bringing its total funding to $300M. Maven plans to use the latest round of funding to advance its end-to-end family care platform to enable deeper personalization to meet the diverse needs of women and families everywhere. Curavit Raises $5M for Digital Therapeutics
Read More
HLTH22: COTA and Google Partner to Use NLP to Harness Unstructured Oncology Data
What You Should Know: COTA, Inc., an oncology real-world data and analytics company announced a partnership with Google Cloud to bring clarity to unstructured oncology data through the latest advancements in machine learning and natural language processing. - Many leading real-world data companies - including COTA - leverage clinicians to manually curate oncology real-world data. While this is a reliable and trusted near-term solution to overcoming the challenges associated with
Read More
COTA Secures New Financing to Accelerate Cancer Research and Treatment Innovation
What You Should Know: - COTA, Inc., an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management and additional capital from existing investors. - The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drug development in oncology. - Perella Weinberg Partners LP served as exclusive financial advisor and Goodwin Procter
Read More
Building a Healthier Future with Real Wireless Power
One of the lessons of the COVID-19 pandemic has been that healthcare facilities need to scale up operations quickly to respond to a public health emergency and that doing so is a significant challenge. In the early days of the pandemic, hard-hit cities like New York and others had to set up mobile hospital units or access additional capacity through military hospital ships. In an emergency like the pandemic, staffing shortages remain a persistent problem, but expanding facility
Read More
COTA Appoints Noel Alaka as VP of Life Sciences
What You Should Know: Today, oncology real-world data analytics company COTA announced the appointment of Noel Alaka as Vice President of Life Sciences. As VP of Life Sciences, Alaka will be responsible for helping grow and build partnerships with leading life sciences companies that are looking to adopt real-world data and real-world evidence to help accelerate innovation in treatments for patients facing cancer. Noel Alaka Bio/Background A benchtop
Read More
4 Steps for Operationalizing the FDA’s Call To Improve Health Outcomes for All Patients
In April, FDA Commissioner Dr. Robert Califf laid out areas of challenge and opportunity when it comes to improving health outcomes, restoring public trust in science, and making the most of our ongoing investments in data analytics and clinical research. More specifically, Califf made clear that our current healthcare system is “very well aligned to improve outcomes for some people and not others.” Califf went on to note that we need better mechanisms for evidence generation
Read More
COTA Promotes Miruna Sasu to President and CEO
What You Should Know: - COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer. - Since April 2021 when she was hired as the company’s chief strategy officer, Miruna has helped spearhead a series of research collaborations focused on investigating racial disparities in cancer care and the drug development process, including partnerships with the University of Chicago
Read More
70% of US Oncologists Are Wrong About Clinical Trial Diversity
What You Should Know: - COTA's study reveals that 70 percent of oncologists believe patient populations enrolled in clinical trials for cancer research are representatively diverse. COTA, Inc., an oncology real-world data and analytics company, announced insights from a study of practicing oncologists that reveals 83 percent of oncologists surveyed believe real-world data is critical to accelerating the development of potentially life-saving cancer drugs and treatments. The study, which
Read More
U of Chicago Med & COTA to Address Racial Disparities in Cancer Using RWD
What You Should Know: - COTA, Inc., an oncology real-world data and analytics company and the University of Chicago Medicine announced a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer. - Multiple myeloma is the second-most-common hematologic malignancy, with an estimated 34,920 new cases and 12,410 deaths expected to occur
Read More
